Not applicableWithdrawnNCT04349111What this trial is testingAn Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite"Who this might be right forInvasive Ductal CarcinomaDuctal Carcinoma In Situ Xoft, Inc.
Not applicableEnded earlyNCT01875198What this trial is testingOncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic CancerWho this might be right forLeft-sided Pancreatic CancerDuctal Adenocarcinoma Yonsei University 1
Not applicableStudy completedNCT01945762What this trial is testingObservational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid CancerWho this might be right forSymptomatic, Aggressive, Sporadic, Unresectable, LocallyAdvanced/Metastatic Medullary Thyroid Cancer (MTC) Genzyme, a Sanofi Company 31
Testing effectiveness (Phase 2)Study completedNCT05052567What this trial is testingCEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal AdenocarcinomaWho this might be right forPancreatic Cancer Qilu Pharmaceutical Co., Ltd. 50
Not applicableUnknownNCT02928081What this trial is testingStandard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head AdenocarcinomaWho this might be right forCarcinoma, Pancreatic Ductal West China Hospital 320
Testing effectiveness (Phase 2)Study completedNCT05900986What this trial is testingLS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast CancerWho this might be right forBreast CancerDCISInvasive Duct Carcinoma of Breast Integro Theranostics 22
Not applicableUnknownNCT05201729What this trial is testingInfluence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic CancerWho this might be right forPancreatic Ductal Adenocarcinoma, PDAC Ruijin Hospital 30
Testing effectiveness (Phase 2)UnknownNCT04913337What this trial is testingStudy of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesWho this might be right forMesotheliomaGlioblastomaRenal Cell Carcinoma+12 more NGM Biopharmaceuticals, Inc 179
Early research (Phase 1)Looking for participantsNCT07106827What this trial is testingGV20-0251 in Advanced or Refractory Solid TumorsWho this might be right forHCC - Hepatocellular CarcinomaCholangiocarcinomaMelanoma+5 more West China Hospital 10
Not applicableStudy completedNCT00084669What this trial is testingVenlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast CancerWho this might be right forBreast CancerHot FlashesSleep Disorders Massachusetts General Hospital 119
Not applicableLooking for participantsNCT05475366What this trial is testingPersonalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic SignaturesWho this might be right forCarcinoma, Pancreatic DuctalPrognosis Institut Curie 85
Testing effectiveness (Phase 2)Study completedNCT00960336What this trial is testingDoxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast CancerWho this might be right forBreast Cancer ARCAGY/ GINECO GROUP 59
Testing effectiveness (Phase 2)Active Not RecruitingNCT04759911What this trial is testingSelpercatinib Before Surgery for the Treatment of RET-Altered Thyroid CancerWho this might be right forMalignant Thyroid Gland NeoplasmPoorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland Carcinoma+4 more M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT02061332What this trial is testingDC Vaccine for Patients With Ductal Carcinoma In SituWho this might be right forBreast CancerDCIS Abramson Cancer Center at Penn Medicine 58
Early research (Phase 1)Study completedNCT02259114What this trial is testingA Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)Who this might be right forNUT Midline CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation+3 more Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 47
Large-scale testing (Phase 3)Not Yet RecruitingNCT07445295What this trial is testingChiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal AdenocarcinomaWho this might be right forMetastatic Pancreatic Ductal Adenocarcinoma Chipscreen Biosciences, Ltd. 558
Testing effectiveness (Phase 2)Study completedNCT02583477What this trial is testingPhase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal CarcinomaWho this might be right forMetastatic Pancreatic Ductal Adenocarcinoma AstraZeneca 23
Testing effectiveness (Phase 2)UnknownNCT03634332What this trial is testingSecond-line Study of PEGPH20 and Pembro for HA High Metastatic PDACWho this might be right forPancreatic Ductal AdenocarcinomaPancreatic CancerPancreatic Neoplasms Pancreatic Cancer Research Team 35
Testing effectiveness (Phase 2)Looking for participantsNCT07627711What this trial is testingDual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal AdenocarcinomaWho this might be right forPancreatic Ductal Adenocarcinoma (PDAC)Unresectable Locally AdvancedMetastatic Disease Beijing Biotech 42
Testing effectiveness (Phase 2)Study completedNCT01839487What this trial is testingPEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic CancerWho this might be right forMetastatic Pancreatic Cancer Halozyme Therapeutics 279